ETON
Eton Pharmaceuticals, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow +30.0% ·
net new positions +20.0%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 68 | +17 | 8.66M | $313.25M | +19 | −2 |
| Q1 2026 | 53 | 0 | 6.86M | $169.02M | +7 | −7 |
| Q4 2025 | 53 | +3 | 7.09M | $119.84M | +3 | — |
| Q3 2025 | 13 | +1 | 6.27M | $136.34M | +1 | — |
| Q2 2025 | 9 | -2 | 4.42M | $63.03M | +1 | −3 |
| Q1 2025 | 8 | +2 | 1.18M | $15.27M | +3 | −1 |
| Q4 2024 | 6 | +2 | 854.61K | $11.39M | +2 | — |
| Q3 2024 | 3 | -1 | 376.73K | $2.26M | +1 | −2 |
| Q2 2024 | 4 | — | 363.35K | $1.20M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Millennium Management ✦ | 355.93K | +156.3% | $4.62M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 298.25K | +11.0% | $3.87M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 3 | Renaissance Technologies ✦ | 274.00K | +41.9% | $3.56M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | State Street Global Advisors ✦ (passive) | 114.24K | +8.4% | $1.48M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Two Sigma Investments ✦ | 82.36K | -26.8% | $1.07M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | Wellington Management ✦ | 25.28K | New | $328,173 | 0.0% | New | 1 | SEC ↗ ×2 |
| 7 | Citadel Advisors ✦ | 24.49K | New | $317,906 | 0.0% | New | 1 | SEC ↗ ×2 |
| 8 | Point72 Asset Management ✦ | 1.50K | New | $19,470 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Wellington Management | $328,173 | 0.0% |
| Citadel Advisors | $317,906 | 0.0% |
| Point72 Asset Management | $19,470 | 0.0% |
Exited
| Marshall Wace | $481,943 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 115 holders, 17.61M shares, $424.10M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 4.17K sh · $229,406
Director · 36.39K sh · $2.13M
Director · 13.48K sh · $811,932
Director · 128 sh · $7,907
Officer · 25.00K sh · $1.63M
Officer, Director · 47.31K sh · $2.85M
Officer, Director · 36.37K sh · $2.22M
Officer, Director · 7.34K sh · $456,085
Officer, Director · 8.98K sh · $562,472
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology